Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) CEO Simeon Kohl purchased 59,000 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were purchased at an average price of $1.79 per share, with a total value of $105,610.00. Following the completion of the acquisition, the chief executive officer directly owned 2,856,385 shares of the company’s stock, valued at approximately $5,112,929.15. This trade represents a 2.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Health Catalyst Trading Up 4.0%
Health Catalyst stock opened at $1.80 on Friday. Health Catalyst, Inc. has a 52 week low of $0.96 and a 52 week high of $3.62. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.70 and a current ratio of 2.70. The firm has a market capitalization of $135.46 million, a PE ratio of -0.49 and a beta of 1.53. The business’s 50-day simple moving average is $1.90 and its 200-day simple moving average is $1.64.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%.The firm had revenue of $70.49 million during the quarter, compared to the consensus estimate of $69.09 million. Equities research analysts forecast that Health Catalyst, Inc. will post -0.18 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of analysts have weighed in on HCAT shares. Citigroup reduced their price target on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Canaccord Genuity Group restated a “hold” rating and set a $1.80 price objective (down from $3.00) on shares of Health Catalyst in a report on Thursday, August 20th. Wells Fargo & Company cut their price objective on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a research report on Thursday, August 13th. Finally, Weiss Ratings upgraded shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $2.45.
Get Our Latest Analysis on HCAT
About Health Catalyst
Health Catalyst, Inc is a healthcare technology and data analytics company that helps healthcare organizations use data to improve clinical outcomes, operational performance and financial results. The company provides software, data management capabilities and professional services designed to support hospitals, health systems, medical groups and other healthcare providers.
Its offerings include the Health Catalyst Data Operating System, which integrates and organizes data from disparate clinical, financial and operational systems, as well as analytics applications for areas such as quality improvement, population health, cost management and care delivery.
Further Reading
- Five stocks we like better than Health Catalyst
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
